ArticleCancer science2007
LKB1 gene mutations in Japanese lung cancer patients.
Article in Cancer science, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 54 citations in OpenAlex.
- Liver kinase B1 expression is associated with improved prognosis and tumor immune microenvironment features in small cell lung cancer.Frontiers in oncology · 2025Article
- Article
- Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic.Current oncology (Toronto, Ont.) · 2022Article
- Effect of Cetuximab andYonago acta medica · 2019Article
- Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer.Cancer control : journal of the Moffitt Cancer Center · 2016Article
- LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.Oncogene · 2016Article
- Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.Translational lung cancer research · 2015Review
- The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss.Oncogene · 2015Article
- Novel mutations and role of the LKB1 gene as a tumor suppressor in renal cell carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Article
- Molecular biology of lung cancer.Journal of thoracic disease · 2013Review
- The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss.Cancer research · 2012Article
- Cancer genes in lung cancer: racial disparities: are there any?Genes & cancer · 2012Article
- Genetic changes in squamous cell lung cancer: a review.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2012Review
- The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival.Annals of oncology : official journal of the European Society for Medical Oncology · 2012Article
- Molecular biology of lung cancer: clinical implications.Clinics in chest medicine · 2011Review
- Liver kinase B1 (LKB1) in the pathogenesis of epithelial cancers.Cancer letters · 2011Review
- LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor.Protein & cell · 2011Review
- LKB1 gene alterations in surgically resectable adenocarcinoma of the lung.Surgery today · 2011Article
- Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutation of the LKB1 gene (also known as STK11) is regarded as a cause of Peutz-Jeghers syndrome. In Caucasian patients, LKB1 somatic mutations occur in approximately one-third of lung adenocarcinomas. The aim of the present study was to examine the LKB1 gene in Japanese patients with lung cancer and to evaluate its clinical and pathological implications. We sequenced the LKB1 gene in 22 lung cancer cell lines and 100 Japanese patients with lung cancer (including 81 adenocarcinomas, 14 squamous cell carcinomas and five other histological types) who had undergone curative pulmonary resection. We also determined expression levels of the LKB1 gene by quantitative real-time reverse transcription-polymerase chain reaction and correlated these results with the clinical and pathological features of patients. Among the 22 cell lines, four had mutations and three of these were in adenocarcinoma cells. Of 100 primary lung cancers, only three had LKB1 gene mutations (3%). All of them were male smokers with adenocarcinomas. Hence, when confined to this subset of patients, the mutation frequency was 9% (3/33). No significant correlation was observed between the expression level of LKB1 and patient clinicopathological features. In conclusion, LKB1 gene mutations were relatively rare in Japanese patients with lung cancer compared with Caucasian patients. LKB1 gene mutations appear to be frequent in male, smoking patients of Caucasian origin, in contrast to EGFR or HER2 mutations that are frequent in non-smoking, female patients of Asian origin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.